Icure Pharmaceutical Incorporation Cash Flow Conversion Efficiency

Latest as of March 2025: -0.055x

Icure Pharmaceutical Incorporation cash flow conversion efficiency. Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has a cash flow conversion efficiency ratio of -0.055x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.28 Billion ≈ $-2.23 Million USD) by net assets (₩59.43 Billion ≈ $40.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Icure Pharmaceutical Incorporation (2015–2024)

Cash flow conversion efficiency of Icure Pharmaceutical Incorporation from 2015 to 2024. This chart illustrates how Icure Pharmaceutical Incorporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 175250 stock price and chart for real-time trading data and today's change.

Icure Pharmaceutical Incorporation Cash Flow Conversion Ratio Explained

Icure Pharmaceutical Incorporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Icure Pharmaceutical Incorporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their cash flow conversion efficiency. Also see 175250 company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
ONDINE BIOMEDICAL INC.CDI F:VF5	N/A
American Creek Resources Ltd V:AMK	-0.114x
Yenher Holdings Bhd KLSE:5300	0.028x
Cryomax Cooling System Corp TW:1587	0.052x
Lithium Ionic Corp V:LTH	-0.182x
Playstudios Inc NASDAQ:MYPS	0.024x
Melhus Sparebank OL:MELG	0.110x
Ailleron S.A. WAR:ALL	0.037x

Annual Cash Flow Conversion Efficiency for Icure Pharmaceutical Incorporation (2015–2024)

The table below shows the annual cash flow conversion efficiency of Icure Pharmaceutical Incorporation from 2015 to 2024. Review Icure Pharmaceutical Incorporation (175250) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩60.26 Billion ≈ $40.84 Million	₩-17.05 Billion ≈ $-11.56 Million	-0.283x	-24.75%
2023-12-31	₩59.59 Billion ≈ $40.39 Million	₩-13.52 Billion ≈ $-9.16 Million	-0.227x	-80.30%
2022-12-31	₩89.67 Billion ≈ $60.77 Million	₩-11.28 Billion ≈ $-7.65 Million	-0.126x	+54.07%
2021-12-31	₩95.76 Billion ≈ $64.89 Million	₩-26.23 Billion ≈ $-17.77 Million	-0.274x	-147.68%
2020-12-31	₩112.15 Billion ≈ $76.01 Million	₩-12.40 Billion ≈ $-8.41 Million	-0.111x	-81.49%
2019-12-31	₩97.53 Billion ≈ $66.10 Million	₩-5.94 Billion ≈ $-4.03 Million	-0.061x	+29.34%
2018-12-31	₩84.69 Billion ≈ $57.40 Million	₩-7.30 Billion ≈ $-4.95 Million	-0.086x	-234.63%
2017-12-31	₩17.47 Billion ≈ $11.84 Million	₩1.12 Billion ≈ $758.55K	0.064x	+122.24%
2016-12-31	₩16.94 Billion ≈ $11.48 Million	₩-4.88 Billion ≈ $-3.31 Million	-0.288x	-741.49%
2015-12-31	₩5.96 Billion ≈ $4.04 Million	₩-204.05 Million ≈ $-138.28K	-0.034x	--

About Icure Pharmaceutical Incorporation

KQ:175250 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$54.96 Million

₩81.09 Billion KRW

Market Cap Rank

#21329 Global

#1258 in Korea

Share Price

₩2170.00

Change (1 day)

+0.00%

52-Week Range

₩2170.00 - ₩2170.00

All Time High

₩23730.97